Objective To investigate the influence of combination therapy of amlodipine and valsartanon on the plasma adiponectin (ADPN) and free fatty acids (FFAs) levels in patients with essential hypertension.
Methods Fifty hypertensive patients were included. After 4 week amlodipine (5mg/d) treatment, 34 patients with diastolic blood pressure (DBP) equal to or more than 90 mmHg were included in the double blind period and randomly divided into amlodipine (amlodipine, 5mg/d) and the combination (amlodipine 5mg + valsartan 80 mg/d) groups for other 8 weeks. BP, blood lipids, blood glucose, ADPN and FFA were measured at baseline, 4 and 12 week after treatment. Eighteen normotensive adults were selected as the control.
Results At baseline, FFA, total cholesterol (TC) and triglycerides (TG) were significantly higher, but ADPN lower in the hypertensive group than in the control group. Four weeks amlodipine treatment increased significantly ADPN levels (4.75 ± 1.88 vs 5.09 ± 1.97 mg/L, P.
Conclusions Four weeks amlodipine monotherapy can significantly increase the plasma ADPN level. On this base, the combination therapy of amlodipine and valsartan can better improve plasma ADPN and FFA than amlodipine monotherapy.